180 Life Sciences Announces Positive Topline Results of a Clinical Pharmacology Study Testing a New Solid Formulation of CBD with Enhanced Oral Uptake

Stock Information for 180 Life Sciences Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About 180 Life Sciences Corp.

180 Life Sciences Corp. Interim CEO, Blair Jordan, Issues Letter to Stockholders; Provides Update on Newly Acquired Gaming Technology Platform
180 Life Sciences Corp. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Rule and Expands into the Global iGaming Sector
180 Life Sciences Corp. - Corporate Updates
180 Life Sciences Announces the Appointment of Omar Jimenez as Chief Financial Officer
180 Life Sciences Granted an Additional Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements
180 Life Sciences Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements
180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement
180 Life Sciences Corp. Announces 1-For 19 Reverse Stock Split as Part of Nasdaq Compliance Plan

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.